Neurocrine Biosciences, Inc. (NBIX) SEC Filings & Earnings Calls

CMO transition may cause temporary disruption in clinical development oversight.

“Change in Chief Medical Officer, a key role for pipeline execution.”

High R&D and SG&A spending

“Research and development $326.7 vs $244.3 for three months ended June 30, 2026 and 2025, respectively.”

Acquisition integration risk

“Acquisition of Soleno for $2.83B adds significant goodwill and intangible assets.”

Customer concentration

“Customer A 34%, Customer B 26%, Customer C 28% of gross product sales for six months ended June 30, 2026.”

Cash burn from acquisition: cash and marketable securities dropped from $2.5B to $482M after Soleno acquisition.

“Total Cash, Cash Equivalents, and Marketable Securities $482 million as of June 30, 2026, down from $2,543 million at December 31, 2025.” · word for word

Pipeline dependency: Phase 3 readouts in 2027 carry binary risk for osavampator and direclidine.

“Multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia.” · word for word

Integration risk of Soleno operations and VYKAT XR commercialization

“Acquisition adds new product and pipeline; integration complexity”

Financial leverage from $2.9B cash acquisition

“Cash tender offer; impact on balance sheet not detailed”

DOJ investigation into INGREZZA sales and marketing

“Received a civil investigative demand from the U.S. Department of Justice requesting certain documents and information related to our sales and marketing of INGREZZA” · word for word

Generic competition for INGREZZA SPRINKLE

“Zydus filed an ANDA with a Paragraph IV certification for a generic version of INGREZZA SPRINKLE”

Integration risk from Soleno acquisition

“Agreed to acquire Soleno Therapeutics for $53.00 per share in cash, equity value approximately $2.9 billion”

Acquisition integration risk: Soleno Therapeutics acquisition for $2.9B may face integration challenges.

“Entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.” · word for word

R&D expense increase: $296.2M GAAP R&D (+$33M YoY) driven by pipeline investments.

“GAAP Research and Development (R&D) $296.2 million... Increased R&D expense in support of an expanded and advancing pre-clinical and clinical portfolio”

Integration risk and potential dilution from acquisition financing.

“Merger involves a subsidiary and tender/support agreements; no financial terms disclosed.”

Dependence on INGREZZA for majority of revenue; competition from AUSTEDO XR and other VMAT2 inhibitors

“INGREZZA represents ~85% of total product sales; head-to-head data shows higher VMAT2 occupancy vs AUSTEDO XR, but competitive pressure remains”

Pricing pressure from formulary access investments may compress net price

“Partially offset by a lower net price due to new formulary access investments to support long-term growth” · word for word

Intellectual property litigation risk

“We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products.” · word for word

Product liability exposure

“The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and CRENESSITY, may expose us to liability claims.” · word for word

Data privacy and security compliance cost

“Our actual or perceived failure to comply with such obligations could have a material adverse effect on our reputation, business, financial condition or results of operations.” · word for word

Key executive transition; potential loss of institutional knowledge if not managed well.

“Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer effective June 2, 2025.” · word for word

Generic competition for INGREZZA SPRINKLE

“In March 2025, we received a notice from Zydus Lifesciences Global FZE (Zydus FZE) that it had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA SPRINKLE (valbenazine).” · word for word

DOJ investigation into INGREZZA marketing

“In August 2025, we received a civil investigative demand from the U.S. Department of Justice (DOJ) requesting certain documents and information related to our sales and marketing of INGREZZA.” · word for word

IRA drug price negotiation risk

“We were notified in January 2025 that INGREZZA qualifies for the small biotech exception, which provides an exemption from selection until 2027 (for initial price applicability year 2029, pursuant to which negotiated pricing would go into effect, if selected).” · word for word

Customer concentration

“Four of these customers represent over 90% of our total gross product sales.” · word for word

R&D and SG&A expenses increasing significantly, potentially pressuring margins if revenue growth slows.

“GAAP R&D $250M vs $195M YoY; GAAP SG&A $291.6M vs $234.3M YoY.”